Isac C Thomas1, Marin Nishimura2, Janet Ma2, Stephen D Dickson2, Laith Alshawabkeh2, Eric Adler2, Alan Maisel2, Michael H Criqui3, Barry Greenberg2. 1. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California. Electronic address: icthomas@ucsd.edu. 2. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California. 3. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California; Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.
Abstract
BACKGROUND: Despite a global epidemic of methamphetamine abuse, methamphetamine-associated heart failure (MethHF) remains poorly understood. We sought to evaluate characteristics and outcomes for patients with MethHF. METHODS: We reviewed the electronic health records of the University of California, San Diego, from 2005 to 2016. We compared characteristics and outcomes between 896 patients with MethHF and 20,576 patients with heart failure (HF) identified using diagnosis codes, urine toxicology, and natriuretic peptides. RESULTS: Compared with HF, patients with MethHF were younger (50±10 vs 67±16 years), predominantly male (72% vs 54%), and had more psychiatric and substance use comorbidities, including mood/anxiety disorders (29% vs 16%) and opioid use (44% vs 7%). MethHF had a higher 5-year HF readmission rate (64±4% vs 45±1%; hazard ratio [HR] 1.53, P < .001) and a lower 10-year total mortality rate (25±3% vs 28±1%; HR 0.85, P = .09). Predictors of poor outcomes included mood/anxiety disorders (HF readmission HR 1.41, P = .04) and opioid abuse (mortality HR 1.52, P = .04). CONCLUSIONS: Patients with MethHF are frequently encumbered by psychiatric and substance abuse comorbidities, and carry a substantial risk of HF readmission and mortality. Comprehensive efforts are needed to stem this emerging epidemic.
BACKGROUND: Despite a global epidemic of methamphetamine abuse, methamphetamine-associated heart failure (MethHF) remains poorly understood. We sought to evaluate characteristics and outcomes for patients with MethHF. METHODS: We reviewed the electronic health records of the University of California, San Diego, from 2005 to 2016. We compared characteristics and outcomes between 896 patients with MethHF and 20,576 patients with heart failure (HF) identified using diagnosis codes, urine toxicology, and natriuretic peptides. RESULTS: Compared with HF, patients with MethHF were younger (50±10 vs 67±16 years), predominantly male (72% vs 54%), and had more psychiatric and substance use comorbidities, including mood/anxiety disorders (29% vs 16%) and opioid use (44% vs 7%). MethHF had a higher 5-year HF readmission rate (64±4% vs 45±1%; hazard ratio [HR] 1.53, P < .001) and a lower 10-year total mortality rate (25±3% vs 28±1%; HR 0.85, P = .09). Predictors of poor outcomes included mood/anxiety disorders (HF readmission HR 1.41, P = .04) and opioid abuse (mortality HR 1.52, P = .04). CONCLUSIONS:Patients with MethHF are frequently encumbered by psychiatric and substance abuse comorbidities, and carry a substantial risk of HF readmission and mortality. Comprehensive efforts are needed to stem this emerging epidemic.
Authors: Paari Dominic; Javaria Ahmad; Hajra Awwab; Md Shenuarin Bhuiyan; Christopher G Kevil; Nicholas E Goeders; Kevin S Murnane; James C Patterson; Kristin E Sandau; Rakesh Gopinathannair; Brian Olshansky Journal: Circ Arrhythm Electrophysiol Date: 2021-12-28
Authors: Michael Osekowski; Adam Trytell; Andre La Gerche; David Prior; Andrew MacIsaac; Elizabeth D Paratz Journal: Am J Cardiovasc Drugs Date: 2022-02-14 Impact factor: 3.283
Authors: Jakrin Kewcharoen; Andrew K Chang; Purvi Parwani; Gary Fraser; Aditya Bharadwaj; Ahmed Seliem; Diane Tran; Liset Stoletniy; Antoine Sakr; Dmitry Abramov Journal: Cardiol Res Date: 2022-04-05